Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 12,001,300 | 11,020,100 | 9,869,200 | 8,930,700 | 7,574,400 |
| Cost of Goods | 1,651,300 | 1,530,500 | 1,262,200 | 1,080,300 | 904,200 |
| Gross Profit | 10,350,000 | 9,489,600 | 8,607,000 | 7,850,400 | 6,670,200 |
| Operating Expenses | 6,177,000 | 9,723,000 | 4,775,200 | 3,543,300 | 3,888,300 |
| Operating Income | 4,173,300 | -232,900 | 3,832,000 | 4,307,400 | 2,782,100 |
| Interest Expense | 13,300 | 30,600 | 44,100 | 54,800 | 61,500 |
| Other Income | 483,200 | 512,000 | 591,900 | -20,200 | 9,800 |
| Pre-tax Income | 4,643,200 | 248,500 | 4,379,800 | 4,232,400 | 2,730,400 |
| Income Tax | 690,000 | 784,100 | 760,200 | 910,400 | 388,300 |
| Net Income Continuous | 3,953,200 | -535,600 | 3,619,600 | 3,322,000 | 2,342,100 |
| Net Income | $3,953,200 | $-535,600 | $3,619,600 | $3,322,000 | $2,342,100 |
| EPS Basic Total Ops | 15.46 | -2.08 | 14.05 | 12.97 | 9.09 |
| EPS Basic Continuous Ops | 15.46 | -2.08 | 14.05 | 12.97 | 9.09 |
| EPS Diluted Total Ops | 15.32 | -2.08 | 13.89 | 12.82 | 9.01 |
| EPS Diluted Continuous Ops | 15.32 | -2.08 | 13.89 | 12.82 | 9.01 |
| EPS Diluted Before Non-Recurring Items | 16.47 | -1.35 | 13.80 | 13.28 | 11.87 |
| EBITDA(a) | $4,383,100 | $-25,700 | $4,013,301 | $4,455,700 | $2,907,700 |